文献速递骨软组织肉瘤与黑色素瘤

卡巴他赛在转移性或不可手术局部晚期去分化脂肪肉瘤中的活性:EORTC软组织与骨肉瘤组(STBSG)的2期研究

Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
PubMed 文献 · JAMA Oncol · 2022-01-01

这项国际多中心、开放标签、单臂2期试验在4个欧洲国家的10家机构开展,纳入转移性或不可手术局部晚期去分化脂肪肉瘤患者,给予卡巴他赛25 mg/m²静脉输注每21天一次。主要终点12周无进展生存率为55%,达到主要研究终点;中位随访21.6个月时中位无进展生存期6个月、中位总生存期21个月,缓解率8%,疾病控制率68%。作者认为卡巴他赛在这些患者中显示出重要活性,值得在3期研究中进一步研究。

要点

  • 12周无进展生存率为55%,达到Simon两阶段设计的主要终点。
  • 中位随访21.6个月时,中位无进展生存期6个月,中位总生存期21个月。
  • 缓解率8%(1例临床缓解、2例部分缓解),疾病控制(部分缓解+疾病稳定)26例(68%)。

核心结论

  • 该非随机2期临床试验达到主要终点,38例患者中21例(55%)在12周时无进展。
  • 结果提示卡巴他赛在转移性或不可手术局部晚期去分化脂肪肉瘤患者中具有重要活性。
  • 作者认为该药值得在这些肿瘤中开展3期研究进一步研究。

研究设计与样本

  • 国际多中心、开放标签、单臂2期试验,由EORTC软组织与骨肉瘤组开展。
  • 2015年3月至2019年3月在4个欧洲国家的10家机构进行。
  • 纳入转移性或局部晚期组织学证实的去分化脂肪肉瘤患者,需过去6个月内有疾病进展证据,且既往化疗不超过1线。
  • 肿瘤块经强制中心复核确认去分化脂肪肉瘤诊断后,患者在注册后72小时内开始治疗。
  • 卡巴他赛25 mg/m²静脉输注1小时,每21天一次,直至不耐受、进展或撤回知情同意。

主要发现

  • 卡巴他赛周期数范围为1至30个周期,中位5个周期;26例(65%)接受至少4个周期。
  • 12周无进展生存率为55%,达到主要研究终点。
  • 中位随访21.6个月时,中位无进展生存期6个月,中位总生存期21个月。
  • 缓解率为8%,包括1例临床缓解和2例部分缓解。
  • 23例(60.5%)患者疾病稳定;26例(68%)达到疾病控制(部分缓解+疾病稳定)。

关键数值与推荐

  • 主要终点阈值:第一阶段17例中至少4例、第二阶段37例中至少11例可评估患者12周无进展。
  • 12周无进展生存率55%,达到主要终点。
  • 中位无进展生存期6个月,中位总生存期21个月(中位随访21.6个月)。
  • 缓解率8%(1例临床缓解、2例部分缓解),疾病控制率68%(26例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment options for patients with unresectable and/or metastatic dedifferentiated liposarcoma (DDLPS) are limited. New drugs are required. OBJECTIVE: To assess whether cabazitaxel demonstrated sufficient antitumor activity in patients with metastatic or inoperable locally advanced DDLPS to justify further investigation in a phase 3 setting. DESIGN, SETTING, AND PARTICIPANTS: This international multicenter, open-label single-arm phase 2 trial was conducted at 10 institutions in 4 European countries from March 2015 to March 2019. Eligible patients had to have metastatic or locally advanced histologically proven DDLPS with evidence of disease progression within the past 6 months and had to have received no more than 1 previous line of chemotherapy. INTERVENTIONS: After mandatory central review of tumor blocks, if the DDLPS diagnosis was confirmed, patients started treatment within 72 hours after registration. Cabazitaxel was administered at a dose of 25 mg/m2 IV infusion over 1 hour every 21 days until intolerance, progression, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) rate at 12 weeks per RECIST 1.1. Based on a Simon 2-stage design, at least 4 of 17 (stage 1) and 11 of 37 (stage 2) eligible and evaluable patients who were progression free at 12 weeks were needed. The final analysis report was completed on November 17, 2021. RESULTS: Forty patients were registered, with 2 patients being ineligible. The number of cycles ranged from 1 to 30, with a median of 5; 26 patients (65%) received at least 4 cycles of cabazitaxel. Progression-free survival at 12 weeks was 55%, achieving the primary study end point. At a median follow-up of 21.6 months, median PFS was 6 months and median OS 21 months. Response rate (RR) was 8% with 1 clinical response (CR) and 2 partial responses (PR). Twenty-three (60.5%) patients had a stable disease (SD). Disease control (PR+SD) was achieved in 26 patients (68%). CONCLUSIONS AND RELEVANCE: This nonrandomized phase 2 clinical trial met its primary end point, with 21 of 38 patients (55%) being progression free at 12 weeks. These results suggest important activity of cabazitaxel in patients with metastatic or inoperable locally advanced DDLPS. The drug is worth being further studied in these tumors in a phase 3 setting.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sanfilippo R, Hayward RL, Musoro J, et al. Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). JAMA Oncol. 2022. PMID: 35980618. doi:10.1001/jamaoncol.2022.3218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。